Lilly Endowment Inc Sells 210,000 Shares of Eli Lilly And Co (NYSE:LLY) Stock

Eli Lilly And Co (NYSE:LLY) major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $119.77, for a total value of $25,151,700.00. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Lilly Endowment Inc also recently made the following trade(s):

  • On Wednesday, November 27th, Lilly Endowment Inc sold 48,953 shares of Eli Lilly And Co stock. The shares were sold at an average price of $117.51, for a total value of $5,752,467.03.
  • On Monday, November 25th, Lilly Endowment Inc sold 109,318 shares of Eli Lilly And Co stock. The shares were sold at an average price of $117.60, for a total transaction of $12,855,796.80.
  • On Thursday, November 21st, Lilly Endowment Inc sold 108,264 shares of Eli Lilly And Co stock. The stock was sold at an average price of $115.14, for a total transaction of $12,465,516.96.
  • On Monday, November 18th, Lilly Endowment Inc sold 10,598 shares of Eli Lilly And Co stock. The stock was sold at an average price of $114.00, for a total transaction of $1,208,172.00.
  • On Monday, November 11th, Lilly Endowment Inc sold 100 shares of Eli Lilly And Co stock. The stock was sold at an average price of $114.07, for a total transaction of $11,407.00.
  • On Wednesday, November 6th, Lilly Endowment Inc sold 173,918 shares of Eli Lilly And Co stock. The shares were sold at an average price of $114.05, for a total transaction of $19,835,347.90.
  • On Monday, November 4th, Lilly Endowment Inc sold 7,003 shares of Eli Lilly And Co stock. The shares were sold at an average price of $114.04, for a total transaction of $798,622.12.
  • On Thursday, October 31st, Lilly Endowment Inc sold 190,000 shares of Eli Lilly And Co stock. The stock was sold at an average price of $114.00, for a total transaction of $21,660,000.00.
  • On Friday, September 20th, Lilly Endowment Inc sold 210,000 shares of Eli Lilly And Co stock. The stock was sold at an average price of $116.37, for a total transaction of $24,437,700.00.

Shares of LLY traded up $0.72 during trading hours on Friday, hitting $120.49. 1,038,871 shares of the stock were exchanged, compared to its average volume of 7,320,711. Eli Lilly And Co has a fifty-two week low of $101.36 and a fifty-two week high of $132.13. The business has a 50-day moving average of $113.31 and a 200-day moving average of $112.49. The firm has a market capitalization of $115.51 billion, a P/E ratio of 21.71, a price-to-earnings-growth ratio of 1.91 and a beta of 0.16. The company has a debt-to-equity ratio of 4.09, a current ratio of 1.17 and a quick ratio of 0.88.

Eli Lilly And Co (NYSE:LLY) last released its earnings results on Wednesday, October 23rd. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.43 by $0.05. The business had revenue of $5.48 billion for the quarter, compared to analyst estimates of $5.50 billion. Eli Lilly And Co had a net margin of 35.10% and a return on equity of 107.99%. Eli Lilly And Co’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.39 earnings per share. As a group, analysts forecast that Eli Lilly And Co will post 5.79 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a $0.645 dividend. This represents a $2.58 annualized dividend and a dividend yield of 2.14%. The ex-dividend date is Thursday, November 14th. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 46.49%.

A number of research firms recently weighed in on LLY. Bank of America assumed coverage on Eli Lilly And Co in a report on Wednesday, October 16th. They issued a “buy” rating and a $133.00 price objective for the company. Cantor Fitzgerald reaffirmed a “buy” rating and set a $143.00 target price on shares of Eli Lilly And Co in a report on Monday. TheStreet raised Eli Lilly And Co from a “c+” rating to a “b-” rating in a report on Friday, November 8th. Finally, UBS Group reduced their price target on Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating on the stock in a research report on Thursday, October 17th. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $130.03.

Hedge funds have recently bought and sold shares of the company. Selective Wealth Management Inc. acquired a new position in Eli Lilly And Co in the third quarter valued at approximately $25,000. Enterprise Trust & Investment Co bought a new stake in shares of Eli Lilly And Co in the 3rd quarter valued at $27,000. Garrett Wealth Advisory Group LLC bought a new stake in shares of Eli Lilly And Co in the 3rd quarter valued at $29,000. Quest Capital Management Inc. ADV acquired a new position in shares of Eli Lilly And Co during the 3rd quarter valued at $34,000. Finally, Prestige Wealth Management Group LLC acquired a new position in shares of Eli Lilly And Co during the 2nd quarter valued at $34,000. 76.51% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: What is the 52-week high/low?

Insider Buying and Selling by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.